Revolution Medicines Advances Daraxonrasib in Phase 3 Pancreatic Cancer Trial After Hitting Key Goals

on

Revolution Medicines began treating patients in the Phase 3 RASolute 303 trial on April 2, 2026, evaluating daraxonrasib as monotherapy and in combination with gemcitabine/nab-paclitaxel versus standard chemotherapy in first-line metastatic PDAC.2

Phase 1/Ib trial showed daraxonrasib + chemotherapy achieved 55% ORR and 90% DCR at 6.9 months median follow-up in first-line metastatic PDAC.13

Long-term Phase 1/Ib data in second-line+ RAS-mutant PDAC (n=38 any RAS) reported 29% confirmed ORR, 95% DCR, 8.1 months median PFS, and 15.6 months median OS at 16.7 months follow-up.3

RASolute 303 enrolls patients irrespective of RAS genotype; primary endpoints are PFS and OS.2

Daraxonrasib is an oral RAS(ON) multi-selective inhibitor targeting >90% of RAS-mutant PDAC cases.23

Sources:

1. https://www.clinicaltrialsarena.com/news/revolution-medicines-daraxonrasib-phase-i-results-2/

2. https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-begins-treating-patients-phase-3-rasolute/

3. https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-shares-new-clinical-results-supporting/